Clinical trial
Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid…
NCT00027677 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00027677 |
|---|---|
| Title | Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors |
| Official title | Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | halofuginone hydrobromide |
| Enrollment | 25 |
| Start date | Aug 1, 2001 |
| Primary completion | Feb 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2012 |
| Countries | Belgium, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: